La vendita allo scoperto per Statera BioPharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Statera BioPharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Statera BioPharma (OTC:STAB) Azioni, Report sulle vendite allo scoperto

Statera BioPharma

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

STATERA BIOPHARMA INC by Statera Biopharma, Inc.

Statera BioPharma Inc

Stabilis Solutions Inc

Stabilus SE

StableXSwap

Stably USD - True USD

TG Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">consensus of 17 cents</a>.
The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190356/tg-therapeutics-reports-first-quarter-2025-financial-results-and-raises-briumvi-full-year-revenue-" rel="noreferrer noopener">consensus of $118.43 million</a>.
Michael S. Weiss, the Company&#8217;s Chairman and Chief Executive Officer, stated, &#8220;2025 is off to a strong start, and I&#8217;m incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI&#8217;s $119.7 million in U.S. net sales, demonstrates the growing confidence in our treatment and the increasing adoption by healthcare providers. This momentum, combined with the positive feedback we&#8217;re hearing from both patients and clinicians, reinforces our belief that we can achieve our long-term goal of BRIUMVI becoming the number one prescribed anti-CD20 treatment based on dynamic market share.&#8221; 
&#8220;In addition to our ongoing BRIUMVI commercialization efforts, we are continuing to invest in innovation, including simplifying the BRIUMVI treatment regimen, advancing subcutaneous BRIUMVI, and developing azer-cel for progressive MS,&#8221; Weiss added.
Briumvi sales reached $119.7 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44439613/stock-of-the-day-tg-therapeutics-breaks-out-may-head-higher" rel="noreferrer noopener">Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher</a>
The company said it presented five-year data from the open-label extension study of the ULTIMATE I &amp; II Phase 3 trials evaluating Briumvi in adult patients with relapsing forms of multiple sclerosis (RMS).
<ul>
<li>The data demonstrated that 92% of patients were free from disability progression after five years of treatment, an annualized relapse rate of 0.02 during year 5 of treatment (equivalent to one relapse occurring every fifty years of patient treatment), and an overall safety profile that remained consistent, with no new safety signals emerging over 5 years of continuous treatment and no observed cases of progressive multifocal leukoencephalopathy (PML) to date.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147899/biogen-beats-q1-earnings-expectations-as-two-newcomer-drug-sales-spike-avoids-tariff-impact" rel="noreferrer noopener">Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact</a>
The company also presented data from the ENHANCE Phase 3b trial evaluating alternative dosing strategies for Briumvi in patients with RMS, which demonstrated that:
<ul>
<li>A single 600 mg Briumvi infusion on Day 1 was well tolerated in individuals with RMS regardless of prior treatment or B-cell depletion status.</li>
<li>Rapid 30-minute Briumvi infusions were well tolerated in patients with RMS.</li>
</ul>
Guidance: TG Therapeutics raised Briumvi&#8217;s U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance.
<ul>
<li>The company raised the total global revenue target to $575 million from prior guidance of $540 million.</li>
</ul>
Briumvi&#8217;s U.S. net product revenue is expected to be $135 million in the second quarter of 2025.
Price Action: TGTX stock was down 13.2% at $37.68 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45199066/berkshire-hathaway-stock-falls-following-buffetts-retirement-as-ceo" target="_blank" rel="noreferrer noopener">Berkshire Hathaway Stock Falls Following Buffett&#8217;s Retirement As CEO</a></li>
</ul>
Photo: Shutterstock

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

TGTX

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

Offerings

MAIA

MAIA Biotechnology Announces $1.08M Private Placement Of 719,999 Shares At $1.50/Share

Valaris Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) ("Valaris" or the "Company") announced today that it has agreed to sell jackup VALARIS 247 to BW Energy ("BWE") for cash proceeds of approximately $108 million. This sale is expected to close in the second half of 2025, subject to customary closing conditions. As part of the sales agreement, BWE will be restricted from using the rig outside of BWE-owned or affiliated properties for the rig's expected remaining useful life.

Valaris Agrees To Sell Jackup VALARIS 247 To BW Energy For Cash Proceeds Of About $108M

Solesence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLSN#NASDAQ">SLSN</a>) reported $14.63 million in sales this quarter. This is a 48.21 percent increase over sales of $9.87 million the same period last year.

SLSN

Solesence Q1 EPS $0.00 Down From $0.02 YoY; Sales $14.63M Up From $9.87M YoY

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) raises FY2025 Adj EPS guidance from $3.05-$3.20 to $3.15-$3.30 vs $3.15 analyst estimate..

New Jersey Resources Raises FY2025 Adj EPS Guidance from $3.05-$3.20 to $3.15-$3.30 vs $3.15 Est

New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) reported quarterly earnings of $1.78 per share which beat the analyst consensus estimate of $1.62 by 9.88 percent. This is a 26.24 percent increase over earnings of $1.41 per share from the same period last year. The company reported quarterly sales of $913.03 million which beat the analyst consensus estimate of $732.00 million by 24.73 percent. This is a 38.78 percent increase over sales of $657.91 million the same period last year.

Earnings Beats

New Jersey Resources Q2 Adj. EPS $1.78 Beats $1.62 Estimate, Sales $913.03M Beat $732.00M Estimate

Accel Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is unchanged from the same period last year. The company reported quarterly sales of $323.91 million which beat the analyst consensus estimate of $318.75 million by 1.62 percent. This is a 7.32 percent increase over sales of $301.82 million the same period last year.

ACEL

Accel Entertainment Q1 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $323.91M Beat $318.75M Estimate

Dividends

Cabot Corporation Board Increases Dividend From $0.43 to $0.45

JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 180.95 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $776.00 million which beat the analyst consensus estimate of $767.97 million by 1.05 percent. This is a 19.09 percent decrease over sales of $959.10 million the same period last year.

JELD

JELD-WEN Holding Q1 Adj. EPS $(0.17) Beats $(0.19) Estimate, Sales $776.00M Beat $767.97M Estimate

Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) affirms FY2025 Adj EPS guidance from $3.95-$4.15 to $3.95-$4.15 vs $4.06 analyst estimate. Raises FY2025 sales outlook from $2.85 billion-$2.90 billion to $2.87 billion-$2.92 billion vs $2.88 billion estimate.

BFAM

Bright Horizons Family Affirms FY2025 Adj EPS Guidance of $3.95-$4.15 vs $4.06 Est; Raises FY2025 Sales Guidance from $2.85B-$2.90B to $2.87B-$2.92B vs $2.88B Est

Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 61.54 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $323.34 million which beat the analyst consensus estimate of $321.00 million by 0.73 percent. This is a 3.28 percent increase over sales of $313.07 million the same period last year.

CRD/A

Crawford Q1 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $323.34M Beat $321.00M Estimate

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) lowers FY2025 sales outlook from $302.00 million-$307.00 million to $297.50 million-$303.50 million vs $304.62 million estimate.

HSTM

HealthStream Lowers FY2025 Sales Guidance from $302.00M-$307.00M to $297.50M-$303.50M vs $304.62M Est

HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.16 by 12.5 percent. This is a 17.65 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $73.48 million which missed the analyst consensus estimate of $74.93 million by 1.93 percent. This is a 1.00 percent increase over sales of $72.76 million the same period last year.

Earnings Misses

HealthStream Q1 GAAP EPS $0.14 Misses $0.16 Estimate, Sales $73.48M Miss $74.93M Estimate

Boot Barn Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) (the "Company" or "Boot Barn") today announced that its Board of Directors has appointed John Hazen as Chief Executive Officer ("CEO"), effective May 5, 2025. Mr. Hazen had been serving as the Company's Interim Chief Executive Officer since November 2024.

Management

BOOT

Boot Barn Holdings Appoints John Hazen As CEO, Effective May 5, 2025

Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) affirms FY2025 sales outlook from $1.32 billion-$1.38 billion to $1.32 billion-$1.38 billion vs $1.34 billion estimate.

Tidewater Affirms FY2025 Sales Guidance of $1.32B-$1.38B vs $1.34B Est

Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) lowers FY2025 Adj EPS guidance from $7.40-$7.80 to $7.15-$7.50 vs $7.52 analyst estimate..

Cabot Lowers FY2025 Adj EPS Guidance from $7.40-$7.80 to $7.15-$7.50 vs $7.52 Est

Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) affirms FY2025 FFO guidance from $1.43-$1.46 to $1.43-$1.46 vs $1.46 analyst estimate..

SBRA

Sabra Health Care REIT Affirms FY2025 FFO Guidance of $1.43-$1.46 vs $1.46 Est

LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) is looking for FY2025 FFO of $2.65-$2.69 vs $2.66 analyst estimate..

LTC Properties Sees FY2025 FFO $2.65-$2.69 vs $2.66 Est

Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.58) by 27.59 percent. This is a 14.29 percent increase over losses of $(0.49) per share from the same period last year.

IMRX

Immuneering Q1 EPS $(0.42) Beats $(0.58) Estimate

Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.85 by 2.7 percent. This is a 6.74 percent increase over earnings of $1.78 per share from the same period last year. The company reported quarterly sales of $936.00 million which missed the analyst consensus estimate of $1.02 billion by 8.61 percent. This is a 8.15 percent decrease over sales of $1.02 billion the same period last year.

Comments

Statera BioPharma

Vendite allo scoperto

Statera BioPharma (OTC:STAB) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO